ARV regimen chosen by treating physician — Competitive Intelligence Brief

ARV regimen chosen by treating physician (ARV regimen chosen by treating physician) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy. Area: Infectious Disease / Virology.

phase 2 Antiretroviral combination therapy Infectious Disease / Virology Small molecule

Target snapshot

ARV regimen chosen by treating physician (ARV regimen chosen by treating physician) — Kristine Patterson, MD. This is a physician-selected antiretroviral regimen tailored to individual patient characteristics and viral resistance profile.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARV regimen chosen by treating physician TARGET	ARV regimen chosen by treating physician	Kristine Patterson, MD	phase 2	Antiretroviral combination therapy
Switch to DRV/cobicistat + 3TC	Switch to DRV/cobicistat + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitor)	HIV protease, CYP3A4, HIV reverse transcriptase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
Abacavir/lamivudine and efavirenz	Abacavir/lamivudine and efavirenz	GlaxoSmithKline	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Combivir+Reyataz	Combivir+Reyataz	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase; HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class
2. Chang Gung Memorial Hospital · 1 drug in this class
3. Danish HIV Research Group · 1 drug in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Hospital Nossa Senhora da Conceicao · 1 drug in this class
6. Kristine Patterson, MD · 1 drug in this class
7. PETHEMA Foundation · 1 drug in this class
8. University of Alberta · 1 drug in this class
9. University of North Carolina, Chapel Hill · 1 drug in this class